Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The company patent portfolio for Imunami Laboratories Pte. Ltd. is focused on Biotechnology & Pharmaceuticals. Currently, the portfolio includes 1 pending office action. This 1 pending office action is being handled within 1 distinct art unit, reflecting a narrow technical scope for the company's current filings. Such a structure often points to a highly targeted intellectual property strategy.
A specific official, 1 distinct examiner, is responsible for the current workload. KONOPELSKI SNAVEL, SARA ELIZABETH is the busiest examiner identified in the data, managing 1 busiest examiner pending office action. This concentration of the busiest examiner pending office action under 1 distinct examiner means that the prosecution strategy must be tailored to the specific individual's tendencies. The data shows that 1 distinct art unit is the venue for the company's current patent office interactions. Practitioners should prepare for an examination process that is entirely dependent on the findings of the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002165 | RECOMBINANT POLYPEPTIDES AND COMBINATIONS FOR USE IN THE TREATMENT OF CANCER | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002165 | RECOMBINANT POLYPEPTIDES AND COMBINATIONS FOR USE IN THE TREATMENT OF CANCER | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18002165 | RECOMBINANT POLYPEPTIDES AND COMBINATIONS FOR USE IN THE TREATMENT OF CANCER | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112Other | Final Rejection | — | Pending | Dec 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImunami Laboratories Pte. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sara Elizabeth Konopelski Snavel has the most, with 1 of Imunami Laboratories Pte. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
